Alseres Pharmaceuticals, Inc.
ALSE · OTC
12/31/2013 | 12/31/2012 | 12/31/2011 | 12/31/2010 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -10.7% | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 95% | 100% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -102.6% | -228% | – | – |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -198.8% | -310% | – | – |
| EPS Diluted | -153.67 | -268.56 | -486.45 | 81.12 |
| % Growth | 42.8% | 44.8% | -699.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |